Ginseng berry extract prevents atherogenesis via anti-inflammatory action by upregulating phase II gene expression

Chun Ki Kim, Dong Hui Cho, Kyu Sun Lee, Dong Keon Lee, Chan Woong Park, Wan Gi Kim, Sang Jun Lee, Kwon Soo Ha, Oh Goo Taeg, Young Guen Kwon, Young Myeong Kim

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Ginseng berry possesses higher ginsenoside content than its root, which has been traditionally used in herbal medicine for many human diseases, including atherosclerosis. We here examined the antiatherogenic effects of the Korean ginseng berry extract (KGBE) and investigated its underlying mechanism of action in vitro and in vivo. Administration of KGBE decreased atherosclerotic lesions, which was inversely correlated with the expression levels of phase II genes to include heme oxygenase-1 (HO-1) and glutamine-cysteine ligase (GCL). Furthermore, KGBE administration suppressed NF-B-mediated expression of atherogenic inflammatory genes (TNF-α, IL-1β, iNOS, COX-2, ICAM-1, and VCAM-1), without altering serum cholesterol levels, in ApoE-/- mice fed a high fat-diet. Treatment with KGBE increased phase II gene expression and suppressed lipopolysaccharide-induced reactive oxygen species production, NF-B activation, and inflammatory gene expression in primary macrophages. Importantly, these cellular events were blocked by selective inhibitors of HO-1 and GCL. In addition, these inhibitors reversed the suppressive effect of KGBE on TNF-α-mediated induction of ICAM-1 and VCAM-1, resulting in decreased interaction between endothelial cells and monocytes. These results suggest that KGBE ameliorates atherosclerosis by inhibiting NF-B-mediated expression of atherogenic genes via upregulation of phase II enzymes and thus has therapeutic or preventive potential for atherosclerosis.

Original languageEnglish
Article number490301
JournalEvidence-based Complementary and Alternative Medicine
Volume2012
DOIs
Publication statusPublished - 2012 Dec 26

Fingerprint

Panax
Fruit
Atherosclerosis
Anti-Inflammatory Agents
Gene Expression
Heme Oxygenase-1
Vascular Cell Adhesion Molecule-1
Intercellular Adhesion Molecule-1
Ligases
Glutamine
Cysteine
Ginsenosides
Herbal Medicine
High Fat Diet
Apolipoproteins E
Interleukin-1
Genes
Lipopolysaccharides
Monocytes
Reactive Oxygen Species

All Science Journal Classification (ASJC) codes

  • Complementary and alternative medicine

Cite this

Kim, Chun Ki ; Cho, Dong Hui ; Lee, Kyu Sun ; Lee, Dong Keon ; Park, Chan Woong ; Kim, Wan Gi ; Lee, Sang Jun ; Ha, Kwon Soo ; Goo Taeg, Oh ; Kwon, Young Guen ; Kim, Young Myeong. / Ginseng berry extract prevents atherogenesis via anti-inflammatory action by upregulating phase II gene expression. In: Evidence-based Complementary and Alternative Medicine. 2012 ; Vol. 2012.
@article{66bd16cf827045819ce7873f7166dacd,
title = "Ginseng berry extract prevents atherogenesis via anti-inflammatory action by upregulating phase II gene expression",
abstract = "Ginseng berry possesses higher ginsenoside content than its root, which has been traditionally used in herbal medicine for many human diseases, including atherosclerosis. We here examined the antiatherogenic effects of the Korean ginseng berry extract (KGBE) and investigated its underlying mechanism of action in vitro and in vivo. Administration of KGBE decreased atherosclerotic lesions, which was inversely correlated with the expression levels of phase II genes to include heme oxygenase-1 (HO-1) and glutamine-cysteine ligase (GCL). Furthermore, KGBE administration suppressed NF-B-mediated expression of atherogenic inflammatory genes (TNF-α, IL-1β, iNOS, COX-2, ICAM-1, and VCAM-1), without altering serum cholesterol levels, in ApoE-/- mice fed a high fat-diet. Treatment with KGBE increased phase II gene expression and suppressed lipopolysaccharide-induced reactive oxygen species production, NF-B activation, and inflammatory gene expression in primary macrophages. Importantly, these cellular events were blocked by selective inhibitors of HO-1 and GCL. In addition, these inhibitors reversed the suppressive effect of KGBE on TNF-α-mediated induction of ICAM-1 and VCAM-1, resulting in decreased interaction between endothelial cells and monocytes. These results suggest that KGBE ameliorates atherosclerosis by inhibiting NF-B-mediated expression of atherogenic genes via upregulation of phase II enzymes and thus has therapeutic or preventive potential for atherosclerosis.",
author = "Kim, {Chun Ki} and Cho, {Dong Hui} and Lee, {Kyu Sun} and Lee, {Dong Keon} and Park, {Chan Woong} and Kim, {Wan Gi} and Lee, {Sang Jun} and Ha, {Kwon Soo} and {Goo Taeg}, Oh and Kwon, {Young Guen} and Kim, {Young Myeong}",
year = "2012",
month = "12",
day = "26",
doi = "10.1155/2012/490301",
language = "English",
volume = "2012",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

Ginseng berry extract prevents atherogenesis via anti-inflammatory action by upregulating phase II gene expression. / Kim, Chun Ki; Cho, Dong Hui; Lee, Kyu Sun; Lee, Dong Keon; Park, Chan Woong; Kim, Wan Gi; Lee, Sang Jun; Ha, Kwon Soo; Goo Taeg, Oh; Kwon, Young Guen; Kim, Young Myeong.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2012, 490301, 26.12.2012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ginseng berry extract prevents atherogenesis via anti-inflammatory action by upregulating phase II gene expression

AU - Kim, Chun Ki

AU - Cho, Dong Hui

AU - Lee, Kyu Sun

AU - Lee, Dong Keon

AU - Park, Chan Woong

AU - Kim, Wan Gi

AU - Lee, Sang Jun

AU - Ha, Kwon Soo

AU - Goo Taeg, Oh

AU - Kwon, Young Guen

AU - Kim, Young Myeong

PY - 2012/12/26

Y1 - 2012/12/26

N2 - Ginseng berry possesses higher ginsenoside content than its root, which has been traditionally used in herbal medicine for many human diseases, including atherosclerosis. We here examined the antiatherogenic effects of the Korean ginseng berry extract (KGBE) and investigated its underlying mechanism of action in vitro and in vivo. Administration of KGBE decreased atherosclerotic lesions, which was inversely correlated with the expression levels of phase II genes to include heme oxygenase-1 (HO-1) and glutamine-cysteine ligase (GCL). Furthermore, KGBE administration suppressed NF-B-mediated expression of atherogenic inflammatory genes (TNF-α, IL-1β, iNOS, COX-2, ICAM-1, and VCAM-1), without altering serum cholesterol levels, in ApoE-/- mice fed a high fat-diet. Treatment with KGBE increased phase II gene expression and suppressed lipopolysaccharide-induced reactive oxygen species production, NF-B activation, and inflammatory gene expression in primary macrophages. Importantly, these cellular events were blocked by selective inhibitors of HO-1 and GCL. In addition, these inhibitors reversed the suppressive effect of KGBE on TNF-α-mediated induction of ICAM-1 and VCAM-1, resulting in decreased interaction between endothelial cells and monocytes. These results suggest that KGBE ameliorates atherosclerosis by inhibiting NF-B-mediated expression of atherogenic genes via upregulation of phase II enzymes and thus has therapeutic or preventive potential for atherosclerosis.

AB - Ginseng berry possesses higher ginsenoside content than its root, which has been traditionally used in herbal medicine for many human diseases, including atherosclerosis. We here examined the antiatherogenic effects of the Korean ginseng berry extract (KGBE) and investigated its underlying mechanism of action in vitro and in vivo. Administration of KGBE decreased atherosclerotic lesions, which was inversely correlated with the expression levels of phase II genes to include heme oxygenase-1 (HO-1) and glutamine-cysteine ligase (GCL). Furthermore, KGBE administration suppressed NF-B-mediated expression of atherogenic inflammatory genes (TNF-α, IL-1β, iNOS, COX-2, ICAM-1, and VCAM-1), without altering serum cholesterol levels, in ApoE-/- mice fed a high fat-diet. Treatment with KGBE increased phase II gene expression and suppressed lipopolysaccharide-induced reactive oxygen species production, NF-B activation, and inflammatory gene expression in primary macrophages. Importantly, these cellular events were blocked by selective inhibitors of HO-1 and GCL. In addition, these inhibitors reversed the suppressive effect of KGBE on TNF-α-mediated induction of ICAM-1 and VCAM-1, resulting in decreased interaction between endothelial cells and monocytes. These results suggest that KGBE ameliorates atherosclerosis by inhibiting NF-B-mediated expression of atherogenic genes via upregulation of phase II enzymes and thus has therapeutic or preventive potential for atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=84871380525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871380525&partnerID=8YFLogxK

U2 - 10.1155/2012/490301

DO - 10.1155/2012/490301

M3 - Article

C2 - 23243449

AN - SCOPUS:84871380525

VL - 2012

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 490301

ER -